Baird Financial Group Inc. Has $111.22 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Baird Financial Group Inc. cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 213,787 shares of the medical research company's stock after selling 955 shares during the quarter. Baird Financial Group Inc. owned 0.06% of Thermo Fisher Scientific worth $111,219,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Barrett & Company Inc. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $28,000. FPC Investment Advisory Inc. acquired a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $28,000. Missouri Trust & Investment Co bought a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $29,000. Pillar Financial Advisors LLC acquired a new position in Thermo Fisher Scientific in the fourth quarter worth approximately $29,000. Finally, Endeavor Private Wealth Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at $30,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the sale, the chief executive officer now directly owns 115,174 shares in the company, valued at $59,506,950.58. This trade represents a 7.99 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 14,075 shares of company stock valued at $7,305,942. 0.33% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. StockNews.com downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Friday, April 25th. Citigroup dropped their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Evercore ISI decreased their price objective on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Stifel Nicolaus reduced their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a report on Thursday, April 24th. Finally, Argus reduced their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Five investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $607.43.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock traded down $14.91 on Tuesday, reaching $407.36. 3,874,201 shares of the stock were exchanged, compared to its average volume of 1,784,512. The firm has a fifty day moving average price of $471.62 and a two-hundred day moving average price of $518.58. Thermo Fisher Scientific Inc. has a twelve month low of $406.50 and a twelve month high of $627.88. The stock has a market cap of $153.78 billion, a PE ratio of 24.64, a PEG ratio of 2.99 and a beta of 0.82. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same period last year, the business posted $5.11 EPS. The business's quarterly revenue was up .2% on a year-over-year basis. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were issued a dividend of $0.43 per share. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.42%. The ex-dividend date of this dividend was Friday, March 14th. Thermo Fisher Scientific's payout ratio is currently 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.